In a clinical trial, fewer treatment-related adverse events were reported with GELSYN-3 compared to Synvisc.35


  • 93% – 97% of patients and investigators scored the global tolerability as good or very good.
  • GELSYN-3 patients showed a 37% reduction in pain medication use.
  • The most common adverse event with GELSYN-3 was injection site pain (0.5%)

GELSYN-3 performed as well as Synvisc in terms of effectiveness and safety, providing patients with long-lasting, clinically relevant pain relief.35